Published by Coherent Market Insights
Posted on September 28, 2021
Vagus nerve stimulation (VNS) is a U.S. Food and Drug Administration (FDA) approved therapy, which involves stimulation of vagus nerve with the help of stimulator that provides electric impulses to vagus nerve. Vagus nerve stimulator is widely used in the treatment of epilepsy, depression, cluster headache, migraine, asthma, bronchoconstriction, exercise-induced bronchospasm, chronic obstructive pulmonary disease (COPD), gastric motility disorder, and irritable bowel syndrome. Currently, there are two types of vagus nerve stimulator present in the market- implantable vagus nerve device and external vagus nerve device. Implantable devices are implanted inside the body surgically. However, the external devices are nob-invasive and are used outside the body
Key Players Profiled in the Vagus Nerve Stimulators Market Report are as follows: ElectroCore, Inc., LivaNova, PLC, SetPoint Medical Corporation, MicroTransponder, Inc., Beijing PINS Medical Co., Ltd., Parasym Ltd., Nervana, LLC, and tVNS Technologies GmbH.
Request Sample Copy of Vagus Nerve Stimulators Report @
https://www.coherentmarketinsights.com/insight/request-sample/2514
In July 2017, electroCore, Inc. launched gammaCore (non-invasive vagus nerve stimulator) for acute treatment of pain associated with episodic cluster headache in adult patients in the U.S. gammaCore is a non-invasive, hand-held medical device applied at the neck and sends gentle, patented electrical stimulation through the skin to activate the vagus nerve, resulting in the reduction of pain.
In June 2017, LivaNova Plc. received the U.S. FDA approval for its VNS therapy system for treatment of patients as young as four years of age with partial onset seizures that are refractory to antiepileptic medications.
Approval and launch of novel products in market is also expected to support the vagus nerve stimulators market growth over the forecast period. For instance, in June 2017, electroCore, Inc. received the U.S. Food and Drug Administration (FDA) 510(k) clearance to market a newer version of gammaCore (non-invasive vagus nerve stimulator) – the gammaCore-S – for acute treatment of pain associated with episodic cluster headache (eCH) in adult patients.
Furthermore, in February 2019, the U.S. Centers for Medicare & Medicaid Services (CMS) finalized its national coverage determination (NCD) for the LivaNova Plc.’s vagus nerve stimulation therapy (VNS Therapy) System for treatment-resistant depression (TRD). Such favorable reimbursements for VNS devices for depression treatment is also expected to increase its adoption and drive vagus nerve stimulators market growth
Enquiry Before Buying This Report:
https://www.coherentmarketinsights.com/insight/talk-to-analyst/2514
Vagus Nerve Stimulators Market Segmentation:
By Product Type:
By Application:
By Distribution Channel:
Why You Should Buy This Report?
• To gain an in-depth understanding of Vagus Nerve Stimulators market globally
• To identify the on-going trends and anticipated growth in the next nine years
• To help industry consultants, Vagus Nerve Stimulators market other stakeholders align their market-centric strategies
• To obtain research-based business decisions and add weight to presentations and marketing strategies
• To gain competitive knowledge of leading market players
Request for Customization:
https://www.coherentmarketinsights.com/insight/request-customization/2514
The report answers questions such as:
• What is the market size and forecast of the Vagus Nerve Stimulators market?
• What are the inhibiting factors and impact of COVID-19 shaping the Vagus Nerve Stimulators market during the forecast period?
• Which are the products/segments/applications/areas to invest in over the forecast period in the Vagus Nerve Stimulators market?
• What is the competitive strategic window for opportunities in the Vagus Nerve Stimulators market?
• What are the technology trends and regulatory frameworks in the Vagus Nerve Stimulators market?
• What are the modes and strategic moves considered suitable for entering the Vagus Nerve Stimulators market?
Note: Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
Contact us:
Mr. Shah
Senior Client Partner – Business Development
sales@coherentmarketinsights.com
www.coherentmarketinsights.com
The post Vagus Nerve Stimulators Market – Frequent approval and launch of novel vagus nerve stimulators by manufacturers is expected to boost the growth of the market appeared first on Gatorledger.
Vagus nerve stimulation (VNS) is a U.S. Food and Drug Administration (FDA) approved therapy, which involves stimulation of vagus nerve with the help of stimulator that provides electric impulses to vagus nerve. Vagus nerve stimulator is widely used in the treatment of epilepsy, depression, cluster headache, migraine, asthma, bronchoconstriction, exercise-induced bronchospasm, chronic obstructive pulmonary disease (COPD), gastric motility disorder, and irritable bowel syndrome. Currently, there are two types of vagus nerve stimulator present in the market- implantable vagus nerve device and external vagus nerve device. Implantable devices are implanted inside the body surgically. However, the external devices are nob-invasive and are used outside the body
Key Players Profiled in the Vagus Nerve Stimulators Market Report are as follows: ElectroCore, Inc., LivaNova, PLC, SetPoint Medical Corporation, MicroTransponder, Inc., Beijing PINS Medical Co., Ltd., Parasym Ltd., Nervana, LLC, and tVNS Technologies GmbH.
Request Sample Copy of Vagus Nerve Stimulators Report @
https://www.coherentmarketinsights.com/insight/request-sample/2514
In July 2017, electroCore, Inc. launched gammaCore (non-invasive vagus nerve stimulator) for acute treatment of pain associated with episodic cluster headache in adult patients in the U.S. gammaCore is a non-invasive, hand-held medical device applied at the neck and sends gentle, patented electrical stimulation through the skin to activate the vagus nerve, resulting in the reduction of pain.
In June 2017, LivaNova Plc. received the U.S. FDA approval for its VNS therapy system for treatment of patients as young as four years of age with partial onset seizures that are refractory to antiepileptic medications.
Approval and launch of novel products in market is also expected to support the vagus nerve stimulators market growth over the forecast period. For instance, in June 2017, electroCore, Inc. received the U.S. Food and Drug Administration (FDA) 510(k) clearance to market a newer version of gammaCore (non-invasive vagus nerve stimulator) – the gammaCore-S – for acute treatment of pain associated with episodic cluster headache (eCH) in adult patients.
Furthermore, in February 2019, the U.S. Centers for Medicare & Medicaid Services (CMS) finalized its national coverage determination (NCD) for the LivaNova Plc.’s vagus nerve stimulation therapy (VNS Therapy) System for treatment-resistant depression (TRD). Such favorable reimbursements for VNS devices for depression treatment is also expected to increase its adoption and drive vagus nerve stimulators market growth
Enquiry Before Buying This Report:
https://www.coherentmarketinsights.com/insight/talk-to-analyst/2514
Vagus Nerve Stimulators Market Segmentation:
By Product Type:
By Application:
By Distribution Channel:
Why You Should Buy This Report?
• To gain an in-depth understanding of Vagus Nerve Stimulators market globally
• To identify the on-going trends and anticipated growth in the next nine years
• To help industry consultants, Vagus Nerve Stimulators market other stakeholders align their market-centric strategies
• To obtain research-based business decisions and add weight to presentations and marketing strategies
• To gain competitive knowledge of leading market players
Request for Customization:
https://www.coherentmarketinsights.com/insight/request-customization/2514
The report answers questions such as:
• What is the market size and forecast of the Vagus Nerve Stimulators market?
• What are the inhibiting factors and impact of COVID-19 shaping the Vagus Nerve Stimulators market during the forecast period?
• Which are the products/segments/applications/areas to invest in over the forecast period in the Vagus Nerve Stimulators market?
• What is the competitive strategic window for opportunities in the Vagus Nerve Stimulators market?
• What are the technology trends and regulatory frameworks in the Vagus Nerve Stimulators market?
• What are the modes and strategic moves considered suitable for entering the Vagus Nerve Stimulators market?
Note: Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
Contact us:
Mr. Shah
Senior Client Partner – Business Development
sales@coherentmarketinsights.com
www.coherentmarketinsights.com
The post Vagus Nerve Stimulators Market – Frequent approval and launch of novel vagus nerve stimulators by manufacturers is expected to boost the growth of the market appeared first on Gatorledger.
Explore more articles in the Research Reports category
